SEAAIS 2019: 74th Annual Meeting
The purpose of this meeting is to engage the participants through oral didactic presentations followed by group discussions. Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board. Case presentations are often utilized to solidify the objectives covered in each presentation.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Southeastern Allergy, Asthma and Immunology (SEAAIS). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by independent educational grants from CSL Behring, Kaleo, Pharming and Stallergenes Greer.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
Upon completion of this activity, participants should be able to:
1. Report the efficacy and safety data on approved monoclonals for asthma.
2. Examine Peanut OIT emerging therapy and treatment options for peanut allergy patients.
3. Analyze the correlation of some infectious diseases with allergy/immunology.
4. Differentiate causes of chronic cough and compare new thoughts on treatment.
5. Review common dermatologic conditions treated by allergists and apply skin biopsy techniques to rule out differential diagnosis.
6. Examine current treatment for Eosinophilic Esophagitis and update attendees on improved treatment options.
7. Demonstrate what COPD is and assess whether is associated with marijuana smoking and review literature for associations between lung cancer and marijuana smoking.
8. Demonstrate the safety and efficacy of AIT in polysensitized patients.
9. Illustrate itch of different types and examine atopic itch and its new management.
10. Examine current treatment for Hereditary Angioedema and update attendees on improved treatment options.
11. Analyze specific PIDs and their connection to autoimmune disease in order to improve the clinical recognition and prompt treatment.
12. Review the clinical phenotype of nasal polyposis and examine the emerging concepts in dysregulation in the Th2 pathway contributing to the pathophysiology.
13. Review symptoms and treatment options for allergic rhinitis and differentiating between entopy and spontaneous reactions.
14. To summarize the current management and therapies for IgE-mediated food allergy and review key findings from clinical trials and other research studies in food allergy treatment.
15. Examine current treatment for eczema, urticaria and angioedema, and update attendees on improved treatment options.
16. Summarize the history and research of alpha gal and demonstrate improvement in the management of care of a patient with alpha gal.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Southeastern Allergy, Asthma and Immunology (SEAAIS). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 12.75 AMA PRA Category 1 Credit™
- 12.75 Attendance